Last updated on July 2019

A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer


Brief description of study

The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair defects in a population of men with metastatic Prostate Cancer (PC) and to use the variants reported to assess biomarker eligibility for niraparib interventional studies.

Clinical Study Identifier: NCT03871816

Find a site near you

Start Over

Kaiser Permanente

Riverside, CA United States
  Connect »

Norton Healthcare

Louisville, KY United States
  Connect »

Massachusetts General

Boston, MA United States
  Connect »

Duke Cancer Institute

Durham, NC United States
  Connect »

Lancaster Urology

Lancaster, PA United States
  Connect »

Atlantic Urology Clinics

Myrtle Beach, SC United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

University of Virginia

Charlottesville, VA United States
  Connect »

INOVA

Fairfax, VA United States
  Connect »

St Vincent's hospital

Darlinghurst, Australia
  Connect »

Ashford Cancer Centre

Kurralta Park, Australia
  Connect »

Pronutrir

Fortaleza, Brazil
  Connect »

Soroka Hospital

Beer-Sheva, Israel
  Connect »

Severance Hospital

Seoul, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Gangnam Severance Hospital

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Hosp. Quiron Madrid Pozuelo

Pozuelo de Alarcon, Spain
  Connect »

Hosp. Clinico Univ. de Santiago

Santiago de Compostela, Spain
  Connect »

First Urology

Jeffersonville, IN United States
  Connect »

Tisch Cancer Institution

New York, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.